| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | GPO2JN4UON |
| InChI Key | JHDKZFFAIZKUCU-ZRDIBKRKSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C20H30N4O2 |
| Molecular Weight | 358.49 |
| AlogP | 3.24 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 10.0 |
| Polar Surface Area | 70.39 |
| Molecular species | BASE |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 26.0 |
| Primary Target | |
|---|---|
| histone deacetylase 10 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 140-2835 | - | 16-27 | 93 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | 126 | - | 107 | 93 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | 82-3162 | - | 23 | 93 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | 126 | - | 43 | 93 | |
|
Unclassified protein
|
- | 70 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Leukemia, Myeloid, Acute | 3 | D015470 | ClinicalTrials |
| Myelodysplastic Syndromes | 2 | D009190 | ClinicalTrials |
| Sarcoma | 2 | D012509 | ClinicalTrials |
| Myeloproliferative Disorders | 2 | D009196 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 2 | D064129 | ClinicalTrials |
| Leukemia | 1 | D007938 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 95071 |
| ChEMBL | CHEMBL1851943 |
| DrugBank | DB05223 |
| EPA CompTox | DTXSID00239196 |
| FDA SRS | GPO2JN4UON |
| Guide to Pharmacology | 8365 |
| PubChem | 49855250 |
| SureChEMBL | SCHEMBL833105 |
| ZINC | ZINC000043152558 |